Unexpectedly, the inhibition of PRMT5 in lung cancer increases CD274 gene expression, eventually activating the PD1/PD-L1 axis and blocking T-cell-mediated antitumor immunity142. The gene discussed is CD274; the disease is lung carcinoma.